Go Pro
→ BofA: Digital Dollar Coming 2025-2030 (From Decentralized Masters) (Ad)tc pixel Free ALGS Stock Alerts

Aligos Therapeutics (ALGS) Financials

Aligos Therapeutics logo
$4.08 -0.61 (-13.01%)
Closing price 07/24/2026 04:00 PM Eastern
Extended Trading
$4.06 -0.03 (-0.61%)
As of 07/24/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Aligos Therapeutics

Annual Income Statements for Aligos Therapeutics

This table shows Aligos Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -52 -109 -128 -96 -88 -131 -24
Consolidated Net Income / (Loss)		 -52 -109 -128 -96 -88 -131 -24
Net Income / (Loss) Continuing Operations		 -52 -109 -128 -96 -88 -131 -24
Total Pre-Tax Income 		-52 -108 -128 -96 -87 -131 -24
Total Operating Income		 -54 -98 -128 -98 -88 -89 -88
Total Gross Profit		 0.00 0.00 4.36 14 16 3.95 2.19
Total Revenue		 0.00 0.00 4.36 14 16 3.95 2.19
Operating Revenue		 - 0.00 4.36 14 16 3.95 2.19
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 54 98 133 111 104 93 90
Selling, General & Admin Expense		 10 18 29 26 31 23 21
Research & Development Expense		 44 80 104 85 73 70 69
Total Other Income / (Expense), net		 1.86 -10 0.02 1.64 1.24 -42 64
Other Income / (Expense), net		 - - 0.13 1.64 1.24 -42 64
Income Tax Expense		 0.09 0.16 0.14 0.11 0.80 0.33 0.31
Basic Earnings per Share		 ($26.04) ($10.87) ($3.22) ($2.25) ($34.20) ($20.94) ($2.45)
Weighted Average Basic Shares Outstanding		 2.01M 9.99M 39.86M 42.70M 2.56M 6.26M 9.88M
Diluted Earnings per Share		 ($26.04) ($10.87) ($3.22) ($2.25) ($34.20) ($20.94) ($2.45)
Weighted Average Diluted Shares Outstanding		 2.01M 9.99M 39.86M 42.70M 2.56M 6.26M 9.88M
Weighted Average Basic & Diluted Shares Outstanding		 2.01M 9.99M 39.86M 42.70M 75.67M 12.23M 12.38M

Quarterly Income Statements for Aligos Therapeutics

This table shows Aligos Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -18 -28 -35 5.06 -19 -82 43 -16 -32 -20 -23
Consolidated Net Income / (Loss)		 -18 -28 -35 5.06 -19 -82 43 -16 -32 -20 -23
Net Income / (Loss) Continuing Operations		 -18 -28 -35 5.06 -19 -82 43 -16 -32 -20 -23
Total Pre-Tax Income 		-18 -28 -35 5.25 -19 -82 43 -16 -31 -20 -23
Total Operating Income		 -19 -26 -22 -26 -20 -21 -19 -19 -28 -22 -27
Total Gross Profit		 3.24 2.68 0.99 1.06 1.27 0.63 0.31 0.97 0.74 0.17 2.83
Total Revenue		 3.24 2.68 0.99 1.06 1.27 0.63 0.31 0.97 0.74 0.17 2.83
Operating Revenue		 3.24 2.68 0.99 1.06 1.27 0.63 0.31 0.97 0.74 0.17 2.83
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 22 29 23 27 21 21 20 20 29 22 30
Selling, General & Admin Expense		 6.44 6.42 6.67 6.38 4.63 5.16 5.05 5.56 5.17 4.95 6.41
Research & Development Expense		 16 22 16 21 17 16 15 14 24 17 23
Total Other Income / (Expense), net		 1.06 -1.93 -13 32 0.96 -62 62 2.89 -3.12 1.96 4.21
Other Income / (Expense), net		 1.06 -1.93 -13 32 0.96 -62 62 2.89 -3.12 1.96 4.21
Income Tax Expense		 0.03 -0.03 0.02 0.19 0.09 0.03 0.04 0.19 0.06 0.03 0.32
Basic Earnings per Share		 ($10.37) ($10.88) ($5.58) $0.81 ($3.07) ($13.11) $5.12 ($1.53) ($3.04) ($2.01) ($2.21)
Weighted Average Basic Shares Outstanding		 1.74M 2.56M 6.25M 6.26M 6.27M 6.26M 8.41M 10.35M 10.37M 9.88M 10.40M
Diluted Earnings per Share		 ($10.37) ($10.88) ($5.58) $0.81 ($3.07) ($13.11) ($2.11) ($1.53) ($3.04) ($2.01) ($2.21)
Weighted Average Diluted Shares Outstanding		 1.74M 2.56M 6.25M 6.27M 6.27M 6.26M 8.71M 10.35M 10.37M 9.88M 10.40M
Weighted Average Basic & Diluted Shares Outstanding		 74.93M 75.67M 78.11M 79.90M 3.59M 12.23M 12.23M 12.30M 15.72M 12.38M 12.38M

Annual Cash Flow Statements for Aligos Therapeutics

This table details how cash moves in and out of Aligos Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 46 151 -34 -106 54 -99 -19
Net Cash From Operating Activities		 -47 -74 -116 -79 -79 -81 -83
Net Cash From Continuing Operating Activities		 -47 -74 -116 -79 -79 -81 -83
Net Income / (Loss) Continuing Operations		 -52 -109 -128 -96 -88 -131 -24
Consolidated Net Income / (Loss)		 -52 -109 -128 -96 -88 -131 -24
Depreciation Expense		 1.40 2.74 3.02 2.31 1.56 1.03 0.93
Amortization Expense		 0.03 0.82 0.85 1.21 1.09 -0.19 -0.31
Non-Cash Adjustments To Reconcile Net Income		 0.50 15 13 14 16 55 -55
Changes in Operating Assets and Liabilities, net		 3.58 16 -4.65 -1.27 -9.53 -4.96 -3.79
Net Cash From Investing Activities		 6.79 33 3.02 -26 45 -18 -38
Net Cash From Continuing Investing Activities		 6.79 33 3.02 -26 45 -18 -38
Purchase of Property, Plant & Equipment		 -2.79 -2.06 -0.89 -0.94 -0.02 -0.13 -0.44
Purchase of Investments		 -70 -45 -19 -104 -0.01 -108 -165
Sale and/or Maturity of Investments		 80 80 23 79 45 90 128
Net Cash From Financing Activities		 86 192 79 0.16 88 0.36 102
Net Cash From Continuing Financing Activities		 86 192 79 0.16 88 0.36 102
Issuance of Common Equity		 0.00 156 80 0.23 43 0.44 102
Other Financing Activities, net		 0.66 -3.05 -0.95 -0.06 45 -0.08 -0.01
Cash Interest Paid		 0.01 0.00 0.00 0.00 0.00 0.00 0.00
Cash Income Taxes Paid		 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Quarterly Cash Flow Statements for Aligos Therapeutics

This table details how cash moves in and out of Aligos Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 -20 65 -111 21 -9.71 1.67 37 -55 23 -24 12
Net Cash From Operating Activities		 -20 -23 -23 -19 -20 -18 -21 -16 -24 -22 -23
Net Cash From Continuing Operating Activities		 -20 -23 -23 -19 -20 -18 -21 -16 -24 -22 -23
Net Income / (Loss) Continuing Operations		 -18 -28 -35 5.06 -19 -82 43 -16 -32 -20 -23
Consolidated Net Income / (Loss)		 -18 -28 -35 5.06 -19 -82 43 -16 -32 -20 -23
Depreciation Expense		 0.31 0.39 0.28 0.26 0.25 0.24 0.19 0.26 0.22 0.26 0.35
Amortization Expense		 0.37 0.38 -0.08 -0.85 0.69 0.06 -0.14 0.01 -1.62 1.43 0.09
Non-Cash Adjustments To Reconcile Net Income		 3.23 4.75 17 -28 1.40 64 -60 -0.84 7.06 -1.14 -2.08
Changes in Operating Assets and Liabilities, net		 -6.20 -0.29 -5.49 4.11 -3.18 -0.39 -3.84 0.93 1.53 -2.41 1.56
Net Cash From Investing Activities		 -0.01 -0.01 -89 40 10 20 -44 -39 48 -2.02 35
Net Cash From Continuing Investing Activities		 -0.01 -0.01 -89 40 10 20 -44 -39 48 -2.02 35
Purchase of Property, Plant & Equipment		 -0.02 -0.01 -0.07 -0.01 -0.03 -0.03 -0.04 -0.11 -0.19 -0.09 -0.07
Purchase of Investments		 -0.00 - -89 - -20 - -64 -39 -22 -39 0.00
Sale and/or Maturity of Investments		 0.01 - 0.00 40 30 20 20 - 70 38 35
Net Cash From Financing Activities		 -0.02 88 -0.02 0.28 -0.00 0.10 102 -0.18 -0.05 0.12 -0.06
Net Cash From Continuing Financing Activities		 -0.02 88 -0.02 0.28 -0.00 0.10 102 -0.18 -0.05 0.12 -0.06
Issuance of Common Equity		 - 43 0.00 0.30 0.00 0.14 102 -0.18 -0.04 0.13 0.00
Other Financing Activities, net		 -0.02 45 -0.02 -0.02 -0.01 -0.04 0.00 -0.00 -0.01 -0.00 -0.06

Annual Balance Sheets for Aligos Therapeutics

This table presents Aligos Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 147 265 235 147 152 70 89
Total Current Assets		 120 250 204 134 141 62 83
Cash & Equivalents		 70 220 187 81 136 37 18
Restricted Cash		 0.54 0.56 0.16 0.12 0.07 0.11 0.11
Short-Term Investments		 48 23 3.92 44 0.00 20 60
Other Current Assets		 2.03 5.94 14 7.60 5.31 5.09 4.91
Plant, Property, & Equipment, net		 8.52 8.01 6.18 4.82 3.26 2.36 1.87
Total Noncurrent Assets		 18 7.28 25 8.33 7.18 5.59 3.80
Other Noncurrent Operating Assets		 7.76 7.28 9.66 8.33 7.18 5.59 3.80
Total Liabilities & Shareholders' Equity		 147 265 235 147 152 70 89
Total Liabilities		 29 45 51 43 59 99 35
Total Current Liabilities		 14 30 39 33 24 22 21
Accounts Payable		 3.77 3.31 3.02 4.74 2.52 2.57 3.98
Accrued Expenses		 7.60 17 25 16 17 16 14
Current Deferred Revenue		 0.00 7.89 7.64 9.21 1.31 0.15 0.00
Other Current Liabilities		 2.45 2.51 2.91 3.14 3.24 3.46 3.73
Total Noncurrent Liabilities		 16 15 12 9.66 36 77 14
Other Noncurrent Operating Liabilities		 16 11 12 9.43 36 77 14
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -65 220 185 104 92 -29 54
Total Preferred & Common Equity		 -65 220 185 104 92 -29 54
Preferred Stock		 - 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 -65 220 185 104 92 -29 54
Common Stock		 1.42 395 487 503 578 589 695
Retained Earnings		 -66 -175 -303 -399 -487 -618 -642
Accumulated Other Comprehensive Income / (Loss)		 -0.12 -0.19 0.45 0.40 0.55 0.45 0.47

Quarterly Balance Sheets for Aligos Therapeutics

This table presents Aligos Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 86 128 109 88 151 135 110 65
Total Current Assets		 75 118 100 80 143 128 103 60
Cash & Equivalents		 70 24 45 35 74 19 42 30
Restricted Cash		 0.07 0.22 0.07 0.11 0.11 0.11 0.11 0.17
Short-Term Investments		 0.00 89 49 40 64 104 57 25
Other Current Assets		 4.14 5.11 4.96 4.79 5.23 4.89 4.23 4.55
Plant, Property, & Equipment, net		 3.65 3.05 2.80 2.58 2.21 2.06 2.04 1.59
Total Noncurrent Assets		 7.56 6.79 6.44 6.03 5.28 4.70 4.29 3.34
Other Noncurrent Operating Assets		 7.56 6.79 6.44 6.03 5.28 4.70 4.29 3.34
Total Liabilities & Shareholders' Equity		 86 128 109 88 151 135 110 65
Total Liabilities		 31 68 42 38 34 33 38 33
Total Current Liabilities		 22 19 24 21 19 20 22 23
Accounts Payable		 2.94 2.84 6.82 2.74 4.46 3.94 4.65 7.64
Accrued Expenses		 12 12 12 14 11 12 14 12
Current Deferred Revenue		 3.95 0.72 1.33 0.66 0.00 0.58 0.17 0.00
Other Current Liabilities		 3.26 3.27 3.36 3.40 3.49 3.54 3.56 3.69
Total Noncurrent Liabilities		 8.56 49 18 17 15 13 16 9.45
Other Noncurrent Operating Liabilities		 8.38 49 18 17 15 13 16 9.45
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 55 60 67 50 116 102 72 32
Total Preferred & Common Equity		 55 60 67 50 116 102 72 32
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 55 60 67 50 116 102 72 32
Common Stock		 513 581 583 585 691 692 694 697
Retained Earnings		 -459 -522 -517 -536 -575 -591 -622 -665
Accumulated Other Comprehensive Income / (Loss)		 0.50 0.48 0.49 0.58 0.45 0.42 0.46 0.44

Annual Metrics And Ratios for Aligos Therapeutics

This table displays calculated financial ratios and metrics derived from Aligos Therapeutics' official financial filings.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 0.00 38,117,910.00 42,616,191.00 42,815,593.00 74,931,848.00 3,587,892.00 15,724,596.00
DEI Adjusted Shares Outstanding		 0.00 1,524,716.00 1,704,648.00 1,712,624.00 2,997,274.00 3,587,892.00 15,724,596.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 -71.19 -75.28 -56.08 -29.25 -36.57 -1.54
Growth Metrics		 - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 219.04% 11.66% -74.60% -44.59%
EBITDA Growth		 0.00% -79.16% -31.87% 25.66% 8.86% -54.37% 82.11%
EBIT Growth		 0.00% -81.03% -31.03% 25.16% 9.44% -50.64% 81.76%
NOPAT Growth		 0.00% -81.03% -31.16% 23.96% 9.69% -1.17% 1.31%
Net Income Growth		 0.00% -107.68% -18.23% 25.16% 8.71% -49.65% 81.56%
EPS Growth		 0.00% 58.26% 70.38% 30.12% 8.71% 38.77% 88.30%
Operating Cash Flow Growth		 0.00% -58.79% -55.75% 31.36% 0.49% -2.21% -2.18%
Free Cash Flow Firm Growth		 0.00% 0.00% -66.87% 27.05% 40.72% 49.85% -513.56%
Invested Capital Growth		 0.00% -117.86% 11.47% -3.60% -98.23% -96.87% 71.62%
Revenue Q/Q Growth		 0.00% 0.00% 9.19% 29.52% -5.22% -34.22% -17.38%
EBITDA Q/Q Growth		 0.00% 0.00% -2.84% 15.30% -2.58% -72.55% 73.24%
EBIT Q/Q Growth		 0.00% 0.00% -2.83% 14.98% -2.44% -70.69% 72.28%
NOPAT Q/Q Growth		 0.00% 0.00% -2.94% 13.53% -3.91% 5.74% -1.44%
Net Income Q/Q Growth		 0.00% 0.00% -2.64% 14.15% -7.35% -70.51% 72.02%
EPS Q/Q Growth		 0.00% 0.00% -9.15% 14.12% -7.35% -70.66% 70.62%
Operating Cash Flow Q/Q Growth		 0.00% -6.70% -18.18% 20.68% -8.03% 5.01% -4.22%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 20.65% 37.51% 64.75% -111.65%
Invested Capital Q/Q Growth		 0.00% 0.00% 19.16% -9.14% -182.01% -247.59% 10.43%
Profitability Metrics		 - - - - - - -
Gross Margin		 0.00% 0.00% 100.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin		 0.00% 0.00% -2,852.15% -664.59% -542.46% -3,296.35% -1,064.14%
Operating Margin		 0.00% 0.00% -2,943.82% -701.66% -567.50% -2,259.92% -4,024.93%
EBIT Margin		 0.00% 0.00% -2,940.79% -689.87% -559.50% -3,317.62% -1,092.36%
Profit (Net Income) Margin		 0.00% 0.00% -2,944.07% -690.63% -564.61% -3,326.01% -1,106.72%
Tax Burden Percent		 100.16% 100.15% 100.11% 100.11% 100.92% 100.25% 101.32%
Interest Burden Percent		 96.55% 110.78% 100.00% 100.00% 100.00% 100.00% 100.00%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -44.60% -64.37% -63.41% -66.55% -89.48% -415.84% -196.92%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% -51.21% -50.22% -58.27% -118.11% -30.11%
Return on Assets (ROA)		 0.00% 0.00% -51.26% -50.28% -58.80% -118.41% -30.50%
Return on Common Equity (ROCE)		 24.70% -29.62% -63.41% -66.55% -89.48% -415.84% -196.92%
Return on Equity Simple (ROE_SIMPLE)		 80.54% -49.33% -69.47% -92.44% -95.22% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -38 -68 -90 -68 -62 -62 -62
NOPAT Margin		 0.00% 0.00% -2,060.67% -491.16% -397.25% -1,581.95% -2,817.45%
Net Nonoperating Expense Percent (NNEP)		 -11.26% -21.52% -17.11% -16.71% -19.86% -71.36% 55.40%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - -66.99% 215.40% -115.02%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 654.44% 189.90% 197.15% 578.71% 947.76%
R&D to Revenue		 0.00% 0.00% 2,389.38% 611.76% 470.35% 1,781.22% 3,177.17%
Operating Expenses to Revenue		 0.00% 0.00% 3,043.82% 801.66% 667.50% 2,359.92% 4,124.93%
Earnings before Interest and Taxes (EBIT)		 -54 -98 -128 -96 -87 -131 -24
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -53 -94 -124 -92 -84 -130 -23
Valuation Ratios		 - - - - - - -
Price to Book Value (P/BV)		 0.00 4.79 2.74 0.39 0.54 0.00 2.74
Price to Tangible Book Value (P/TBV)		 0.00 4.79 2.74 0.39 0.54 0.00 2.74
Price to Revenue (P/Rev)		 0.00 0.00 116.05 2.93 3.20 36.23 67.04
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 68.79 0.00 0.00 21.77 31.38
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.09 -1.10 -1.11 -1.15 -1.34 -3.06 -5.49
Leverage Ratio		 1.25 1.22 1.24 1.32 1.52 3.51 6.46
Compound Leverage Factor		 1.21 1.35 1.24 1.32 1.52 3.51 6.46
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 155.37% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 -55.37% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 2.09 12.83 3.26 -4.48 -4.86 -16.89 -7.67
Noncontrolling Interest Sharing Ratio		 155.37% 53.99% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - -
Current Ratio		 8.70 8.26 5.25 4.03 5.90 2.86 3.90
Quick Ratio		 8.52 8.04 4.90 3.80 5.68 2.62 3.67
Cash Flow Metrics		 - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -55 -93 -68 -40 -20 -123
Operating Cash Flow to CapEx		 -1,678.64% -3,598.01% -12,966.59% -8,418.77% -415,773.68% -62,110.00% -18,879.41%
Free Cash Flow to Firm to Interest Expense		 0.00 -5.26 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 -7.04 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 -7.24 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - -
Asset Turnover		 0.00 0.00 0.02 0.07 0.10 0.04 0.03
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.61 2.53 3.85 1.40 1.03
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - -
Invested Capital		 -11 -24 -21 -22 -44 -86 -24
Invested Capital Turnover		 0.00 0.00 -0.19 -0.64 -0.47 -0.06 -0.04
Increase / (Decrease) in Invested Capital		 0.00 -13 2.76 -0.77 -22 -42 62
Enterprise Value (EV)		 204 810 300 -85 -86 86 69
Market Capitalization		 150 1,054 506 41 50 143 147
Book Value per Share		 ($32.33) $5.77 $4.33 $2.43 $1.23 ($8.08) $3.41
Tangible Book Value per Share		 ($32.33) $5.77 $4.33 $2.43 $1.23 ($8.08) $3.41
Total Capital		 117 220 185 104 92 -29 54
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -128 -244 -206 -126 -136 -57 -78
Capital Expenditures (CapEx)		 2.79 2.06 0.89 0.94 0.02 0.13 0.44
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -12 -24 -25 -26 -19 -17 -16
Debt-free Net Working Capital (DFNWC)		 106 220 165 100 117 40 62
Net Working Capital (NWC)		 106 220 165 100 117 40 62
Net Nonoperating Expense (NNE)		 14 40 39 28 26 69 -37
Net Nonoperating Obligations (NNO)		 -128 -244 -206 -126 -136 -57 -78
Total Depreciation and Amortization (D&A)		 1.42 3.56 3.86 3.52 2.65 0.84 0.62
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% -583.41% -183.55% -119.75% -421.93% -746.80%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 3,795.99% 722.05% 754.58% 1,024.18% 2,819.26%
Net Working Capital to Revenue		 0.00% 0.00% 3,795.99% 722.05% 754.58% 1,024.18% 2,819.26%
Earnings Adjustments		 - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 ($271.75) ($80.50) ($56.25) ($34.00) ($20.94) ($2.45)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 1.53M 1.71M 1.72M 2.57M 6.26M 9.88M
Adjusted Diluted Earnings per Share		 $0.00 ($271.75) ($80.50) ($56.25) ($34.00) ($20.94) ($2.45)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 1.53M 1.71M 1.72M 2.57M 6.26M 9.88M
Adjusted Basic & Diluted Earnings per Share		 $0.00 ($271.75) ($80.50) ($56.25) $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 399.53K 1.59M 1.71M 3.03M 12.23M 12.38M
Normalized Net Operating Profit after Tax (NOPAT)		 -38 -68 -90 -68 -62 -62 -62
Normalized NOPAT Margin		 0.00% 0.00% -2,060.67% -491.16% -397.25% -1,581.95% -2,817.45%
Pre Tax Income Margin		 0.00% 0.00% -2,940.79% -689.87% -559.50% -3,317.62% -1,092.36%
Debt Service Ratios		 - - - - - - -
EBIT to Interest Expense		 0.00 -9.28 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 -6.49 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 -9.47 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 -6.69 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Aligos Therapeutics

This table displays calculated financial ratios and metrics derived from Aligos Therapeutics' official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 43,502,582.00 74,931,848.00 75,668,521.00 78,109,927.00 79,902,567.00 3,587,892.00 12,228,622.00 12,229,602.00 12,302,748.00 15,724,596.00 12,375,614.00
DEI Adjusted Shares Outstanding		 1,740,103.00 2,997,274.00 3,026,741.00 3,124,397.00 3,196,103.00 3,587,892.00 12,228,622.00 12,229,602.00 12,302,748.00 15,724,596.00 12,375,614.00
DEI Earnings Per Adjusted Shares Outstanding		 -10.37 -9.31 -11.52 1.62 -6.03 -22.90 3.52 -1.30 -2.56 -1.26 -1.86
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 -21.12% -24.20% -63.79% -84.59% -60.82% -76.54% -68.46% -9.05% -41.61% -73.13% 809.97%
EBITDA Growth		 2.78% -24.19% -55.07% 126.71% -5.19% -201.41% 224.67% -431.13% -80.34% 77.80% -151.60%
EBIT Growth		 3.49% -23.10% -52.03% 129.11% -6.42% -194.12% 223.80% -398.63% -64.24% 75.83% -152.68%
NOPAT Growth		 -0.65% -14.62% 7.83% -90.04% -5.56% 20.90% -24.57% 48.96% -40.88% -6.08% 1.94%
Net Income Growth		 3.11% -27.44% -51.88% 126.93% -6.75% -194.53% 223.59% -413.44% -63.75% 75.80% -153.47%
EPS Growth		 3.11% -27.44% -51.88% 126.93% 70.40% -20.50% 62.19% -288.89% 0.98% 84.67% -4.74%
Operating Cash Flow Growth		 -18.67% -35.01% -1.60% -43.16% 1.16% 18.78% 8.08% 20.46% -21.11% -18.16% -10.61%
Free Cash Flow Firm Growth		 6.88% 122.86% 162.74% -32.97% 73.20% 708.72% -376.68% 0.76% -258.64% -375.23% 66.59%
Invested Capital Growth		 23.29% -98.23% -176.27% -28.86% -59.73% -96.87% 59.57% 22.60% -10.11% 71.62% -8.83%
Revenue Q/Q Growth		 -52.96% -17.23% -63.22% 7.61% 19.60% -50.43% -50.56% 210.29% -23.21% -77.19% 1,574.56%
EBITDA Q/Q Growth		 0.52% -56.64% -27.61% 113.43% -491.71% -348.84% 152.78% -135.68% -113.33% 44.75% -22.71%
EBIT Q/Q Growth		 0.12% -55.02% -24.77% 115.07% -465.10% -328.44% 152.52% -136.35% -100.80% 36.94% -14.47%
NOPAT Q/Q Growth		 0.37% -36.32% 15.20% -65.00% 44.66% -2.15% -33.55% 32.39% -52.75% 23.08% -23.45%
Net Income Q/Q Growth		 3.99% -54.60% -24.99% 114.52% -480.54% -326.55% 152.45% -136.82% -98.81% 36.96% -15.89%
EPS Q/Q Growth		 3.99% -54.60% -24.99% 114.52% -479.01% -327.04% 83.91% 27.49% -98.69% 33.88% -9.95%
Operating Cash Flow Q/Q Growth		 -49.35% -11.42% -0.39% 14.30% -3.12% 8.45% -13.62% 25.85% -57.02% 10.68% -6.36%
Free Cash Flow Firm Q/Q Growth		 -24.18% 119.13% 431.16% -205.36% 74.97% 677.42% -281.72% 62.21% 9.57% -343.14% 77.94%
Invested Capital Q/Q Growth		 27.07% -182.01% -21.17% 48.29% 9.60% -247.59% 75.12% 1.00% -28.61% 10.43% 4.57%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin		 -535.07% -1,012.57% -3,513.29% 438.64% -1,436.56% -13,008.59% 13,886.82% -1,596.99% -4,436.71% -10,747.34% -787.53%
Operating Margin		 -588.79% -969.68% -2,235.90% -2,489.54% -1,586.37% -3,269.16% -6,187.46% -1,924.04% -3,827.40% -12,907.69% -951.55%
EBIT Margin		 -556.10% -1,041.48% -3,533.37% 494.82% -1,510.48% -13,056.12% 13,868.49% -1,624.66% -4,248.45% -11,746.15% -802.93%
Profit (Net Income) Margin		 -556.99% -1,040.36% -3,535.80% 477.00% -1,517.65% -13,060.41% 13,854.66% -1,643.83% -4,256.01% -11,763.91% -814.13%
Tax Burden Percent		 100.16% 99.89% 100.07% 96.40% 100.47% 100.03% 99.90% 101.18% 100.18% 100.15% 101.40%
Interest Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Effective Tax Rate		 0.00% 0.00% 0.00% 3.60% 0.00% 0.00% 0.10% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -92.37% -89.48% -137.79% -110.67% -146.69% -415.84% -60.44% -87.74% -141.82% -196.92% -121.86%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 -72.92% -108.46% -390.42% 36.68% -103.95% -464.82% 325.55% -42.35% -113.44% -323.74% -35.10%
Return on Assets (ROA)		 -73.03% -108.35% -390.69% 35.36% -104.45% -464.97% 325.23% -42.85% -113.64% -324.23% -35.59%
Return on Common Equity (ROCE)		 -92.37% -89.48% -137.79% -110.67% -146.69% -415.84% -60.44% -87.74% -141.82% -196.92% -121.86%
Return on Equity Simple (ROE_SIMPLE)		 -148.98% 0.00% -166.54% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -13 -18 -15 -25 -14 -14 -19 -13 -20 -15 -19
NOPAT Margin		 -412.16% -678.77% -1,565.13% -2,399.91% -1,110.46% -2,288.41% -6,181.29% -1,346.83% -2,679.18% -9,035.38% -666.09%
Net Nonoperating Expense Percent (NNEP)		 -4.41% -7.41% -17.94% 32.91% -7.12% -70.28% 49.73% -2.63% -13.44% -6.83% -4.34%
Return On Investment Capital (ROIC_SIMPLE)		 - -19.76% -25.71% -37.88% -28.02% 49.68% -16.49% -12.76% -27.59% -28.52% -59.30%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 198.92% 239.50% 676.06% 600.94% 364.54% 820.67% 1,624.44% 575.75% 697.03% 2,926.04% 226.40%
R&D to Revenue		 489.87% 830.18% 1,659.84% 1,988.60% 1,321.83% 2,548.49% 4,663.02% 1,448.29% 3,230.36% 10,081.66% 825.16%
Operating Expenses to Revenue		 688.79% 1,069.68% 2,335.90% 2,589.54% 1,686.37% 3,369.16% 6,287.46% 2,024.04% 3,927.40% 13,007.69% 1,051.55%
Earnings before Interest and Taxes (EBIT)		 -18 -28 -35 5.25 -19 -82 43 -16 -31 -20 -23
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -17 -27 -35 4.65 -18 -82 43 -15 -33 -18 -22
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.59 0.54 1.24 0.41 0.55 0.00 0.87 0.87 1.68 2.74 2.89
Price to Tangible Book Value (P/TBV)		 0.59 0.54 1.24 0.41 0.55 0.00 0.87 0.87 1.68 2.74 2.89
Price to Revenue (P/Rev)		 1.98 3.20 5.38 3.43 4.62 36.23 30.85 27.78 45.57 67.04 19.54
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 21.77 0.00 0.00 8.12 31.38 7.84
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.20 -1.34 -1.50 -1.36 -1.38 -3.06 -1.42 -1.29 -1.43 -5.49 -1.30
Leverage Ratio		 1.41 1.52 1.73 1.57 1.66 3.51 1.58 1.44 1.63 6.46 1.45
Compound Leverage Factor		 1.41 1.52 1.73 1.57 1.66 3.51 1.58 1.44 1.63 6.46 1.45
Debt to Total Capital		 0.34% 0.00% 0.36% 0.00% 0.37% 0.00% 0.10% 0.00% 0.17% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.34% 0.00% 0.36% 0.00% 0.37% 0.00% 0.10% 0.00% 0.17% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 99.66% 100.00% 99.64% 100.00% 99.63% 100.00% 99.90% 100.00% 99.83% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.86 0.00 1.17 0.00 0.99 0.00 2.64 0.00 1.14 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 1.18 0.00 1.87 0.00 1.13 0.00 2.28 0.00 1.63 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 -6.63 -3.57 -4.92 -5.18 -7.90 -14.60 -1.62 -3.93 -6.06 -7.52 -13.16
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 3.32 5.90 6.25 4.23 3.81 2.86 7.56 6.31 4.70 3.90 2.56
Quick Ratio		 3.13 5.68 5.97 4.01 3.58 2.62 7.28 6.07 4.51 3.67 2.35
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -18 3.45 18 -19 -4.84 28 -51 -19 -17 -77 -17
Operating Cash Flow to CapEx		 -107,031.58% -323,685.71% -32,965.22% -278,471.43% -77,311.54% -65,725.00% -48,625.58% -14,223.85% -12,613.99% -23,635.87% -33,518.84%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.13 0.10 0.11 0.07 0.07 0.04 0.02 0.03 0.03 0.03 0.04
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 3.68 3.85 3.72 2.36 1.93 1.40 1.24 1.31 1.15 1.03 2.47
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -15 -44 -53 -27 -25 -86 -21 -21 -27 -24 -23
Invested Capital Turnover		 -0.92 -0.47 -0.38 -0.33 -0.30 -0.06 -0.09 -0.13 -0.10 -0.04 -0.21
Increase / (Decrease) in Invested Capital		 4.70 -22 -34 -6.13 -9.25 -42 32 6.19 -2.50 62 -1.89
Enterprise Value (EV)		 -38 -86 -39 -67 -47 86 -37 -35 21 69 37
Market Capitalization		 32 50 74 27 28 143 101 88 121 147 92
Book Value per Share		 $1.26 $1.23 $0.79 $0.86 $0.63 ($8.08) $9.52 $8.33 $5.84 $3.41 $2.57
Tangible Book Value per Share		 $1.26 $1.23 $0.79 $0.86 $0.63 ($8.08) $9.52 $8.33 $5.84 $3.41 $2.57
Total Capital		 55 92 60 67 50 -29 117 102 72 54 32
Total Debt		 0.19 0.00 0.22 0.00 0.19 0.00 0.12 0.00 0.12 0.00 0.00
Total Long-Term Debt		 0.19 0.00 0.22 0.00 0.19 0.00 0.12 0.00 0.12 0.00 0.00
Net Debt		 -70 -136 -113 -95 -75 -57 -138 -123 -99 -78 -55
Capital Expenditures (CapEx)		 0.02 0.01 0.07 0.01 0.03 0.03 0.04 0.11 0.19 0.09 0.07
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -18 -19 -14 -19 -16 -17 -14 -15 -18 -16 -19
Debt-free Net Working Capital (DFNWC)		 52 117 99 76 59 40 124 108 81 62 36
Net Working Capital (NWC)		 52 117 99 76 59 40 124 108 81 62 36
Net Nonoperating Expense (NNE)		 4.69 9.69 19 -31 5.17 68 -62 2.87 12 4.61 4.19
Net Nonoperating Obligations (NNO)		 -70 -136 -113 -95 -75 -57 -138 -123 -99 -78 -55
Total Depreciation and Amortization (D&A)		 0.68 0.78 0.20 -0.60 0.94 0.30 0.06 0.27 -1.40 1.69 0.44
Debt-free, Cash-free Net Working Capital to Revenue		 -111.86% -119.75% -99.85% -233.46% -269.57% -421.93% -419.39% -484.44% -671.13% -746.80% -399.06%
Debt-free Net Working Capital to Revenue		 318.43% 754.58% 719.14% 954.01% 981.59% 1,024.18% 3,799.91% 3,392.53% 3,078.16% 2,819.26% 771.67%
Net Working Capital to Revenue		 318.43% 754.58% 719.14% 954.01% 981.59% 1,024.18% 3,799.91% 3,392.53% 3,078.16% 2,819.26% 771.67%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($10.25) ($272.00) ($5.50) $0.75 ($3.07) ($13.11) $5.12 ($1.53) ($3.04) ($2.01) ($2.21)
Adjusted Weighted Average Basic Shares Outstanding		 1.74M 102.54K 6.25M 6.26M 6.27M 6.26M 8.41M 10.35M 10.37M 9.88M 10.40M
Adjusted Diluted Earnings per Share		 ($10.25) ($272.00) ($5.50) $0.75 ($3.07) ($13.11) ($2.11) ($1.53) ($3.04) ($2.01) ($2.21)
Adjusted Weighted Average Diluted Shares Outstanding		 1.74M 102.54K 6.25M 6.27M 6.27M 6.26M 8.71M 10.35M 10.37M 9.88M 10.40M
Adjusted Basic & Diluted Earnings per Share		 $0.00 ($272.00) $0.00 $0.00 $0.00 ($13.11) $0.00 $0.00 $0.00 ($2.01) $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 3.00M 3.03M 3.12M 3.20M 3.59M 12.23M 12.23M 12.30M 15.72M 12.38M 12.38M
Normalized Net Operating Profit after Tax (NOPAT)		 -13 -18 -15 -25 -14 -14 -19 -13 -20 -15 -19
Normalized NOPAT Margin		 -412.16% -678.77% -1,565.13% -2,399.91% -1,110.46% -2,288.41% -6,181.29% -1,346.83% -2,679.18% -9,035.38% -666.09%
Pre Tax Income Margin		 -556.10% -1,041.48% -3,533.37% 494.82% -1,510.48% -13,056.12% 13,868.49% -1,624.66% -4,248.45% -11,746.15% -802.93%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Aligos Therapeutics’ latest quarter shows a company with a strong cash position, but ongoing operating losses remain substantial. In Q1 2026, ALGS generated $2.83 million of revenue, but posted a net loss of $23.0 million and negative operating cash flow of $23.1 million. The key takeaway for retail investors is that the balance sheet still has meaningful liquidity, yet the business is still burning cash at a high rate.

  • Cash, restricted cash, and short-term investments totaled about $55.1 million at the end of Q1 2026, giving the company near-term financial flexibility.
  • The company generated $11.7 million of net cash in Q1 2026, helped by a large $35.0 million sale/maturity of investments.
  • Revenue rose sharply year over year, from $311,000 in Q1 2025 to $2.83 million in Q1 2026.
  • Balance sheet equity improved from $31.8 million in Q1 2026, up from $27.7 million at the end of Q4 2025, reflecting a more stable capital base than earlier periods.
  • Q1 2026 revenue was still modest relative to expenses, so the business remains far from operating break-even.
  • The quarter included $4.2 million of other income, which helped reduce losses but may not be repeatable at the same level.
  • Share count has fluctuated over the last year, which can affect per-share results and suggests some dilution pressure from financing activity.
  • Operating expenses remained very high at $29.8 million in Q1 2026, versus just $2.8 million of gross profit.
  • Net loss widened slightly year over year, from $19.9 million in Q4 2025 to $23.0 million in Q1 2026.
  • Operating cash flow was negative $23.1 million in the quarter, showing the company is still consuming cash from its core business.
  • Over the past several quarters, Aligos has consistently posted sizable losses and negative operating cash flow, underscoring continued dependence on its cash reserves and investment portfolio.

Longer-term trend: ALGS has improved its liquidity profile compared with early 2024, when cash and investments were much higher but the company also reported steep losses and large cash burn. Since then, the company has reduced its cash base and still has not established a consistent path to profitability. Investors should watch future quarters for sustained revenue growth, expense control, and whether investment sales or financing are needed to support operations.

07/26/26 12:18 PM ETAI Generated. May Contain Errors.

Aligos Therapeutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Aligos Therapeutics' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Aligos Therapeutics' net income appears to be on a downward trend, with a most recent value of -$24.19 million in 2025, falling from -$52.26 million in 2019. The previous period was -$131.21 million in 2024. See Aligos Therapeutics' forecast for analyst expectations on what's next for the company.

Aligos Therapeutics' total operating income in 2025 was -$87.99 million, based on the following breakdown:
  • Total Gross Profit: $2.19 million
  • Total Operating Expenses: $90.17 million

Over the last 6 years, Aligos Therapeutics' total revenue changed from $0.00 in 2019 to $2.19 million in 2025, a change of 218,600,000.0%.

Aligos Therapeutics' total liabilities were at $34.99 million at the end of 2025, a 64.7% decrease from 2024, and a 19.3% increase since 2019.

In the past 6 years, Aligos Therapeutics' cash and equivalents has ranged from $18.30 million in 2025 to $220.38 million in 2020, and is currently $18.30 million as of their latest financial filing in 2025.

Over the last 6 years, Aligos Therapeutics' book value per share changed from -32.33 in 2019 to 3.41 in 2025, a change of -110.5%.


Related Companies

Financial statements for NASDAQ:ALGS last updated on 7/16/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
The pact that ran the world and dollar just expired
In 1974, a U.S.-Saudi deal tied oil sales exclusively to dollars, forcing nations worldwide to hold dollars an...
Golden Portfolio | Sponsoredtc pixel
The comeback story of the century (ticker inside)
In 2013, this struggling PC maker went private amid skepticism from Forbes and the New York Times. Instead of ...
InvestorPlace | Sponsoredtc pixel
Universal basic income is not impossible. It exist (kind of)
Robert Kiyosaki, author of Rich Dad Poor Dad, is highlighting an income strategy he calls the Patriot Income P...
Freedom Financial | Sponsoredtc pixel
The REAL Reason Trump is Invading Iran
For a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Be...
Banyan Hill Publishing | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
Three oil giants buried the same discovery for 50 years
In 1976, Chevron tapped an energy source with no fuel costs, no carbon, and no supply chain - then killed the ...
Behind the Markets | Sponsoredtc pixel
The 90%-off options that empty accounts
A call that cost $3.00 last month now trades for $0.30 - a 90% discount that looks tempting. It's not a bar...
Profits Run | Sponsoredtc pixel
This tiny piece of glass could be bigger than GPUs
Jensen Huang says AI can't scale without it. Google Ventures calls it the future of AI compute. Sequoia Capita...
Brownstone Research | Sponsoredtc pixel